Abstract:PURPOSE: Intraocular vascular diseases are leading causes of adult vision loss, and in the mid-1900s, I. C. Michaelson postulated that the retina releases a soluble, diffusible factor that causes abnormal vascular growth and leakage. What became known as "Factor X" eluded investigators for decades.METHODS: The field of cancer research, where Judah Folkman pioneered the concept of angiogenesis, provided the inspiration for the work honored by the 2014 Champalimaud Vision Award. Recognizing that tumors recruit their own blood supply to achieve critical mass, Dr Folkman proposed that angiogenic factors could be therapeutic targets in cancer. Napoleone Ferrara identified vascular endothelial growth factor (VEGF) as such an angiogenic agent: stimulated by hypoxic tumor tissue, secreted, and able to induce neovascularization. VEGF also was a candidate for Factor X, and the 2014 Champalimaud Laureates and colleagues worked individually and collaboratively to identify the role of VEGF in ocular disease.RESULTS: The Champalimaud Laureates correlated VEGF with ocular neovascularization in animal models and in patients. Moreover, they showed that VEGF not only was sufficient, but it also was required to induce neovascularization in normal animal eyes, as VEGF inhibition abolished ocular neovascularization in key animal models.CONCLUSIONS: The identification of VEGF as Factor X altered the therapeutic paradigms for age-related macular degeneration (AMD), diabetic retinopathy, retinal vein occlusion, and other retinal disorders.TRANSLATIONAL RELEVANCE: The translation of VEGF from discovery to therapy resulted in the most successful applications of antiangiogenic therapy to date. Annually, over one million patients with eye disease are treated with anti-VEGF agents.

VEGF in Signaling and Disease: Beyond Discovery and Development

Biology and therapeutic targeting of vascular endothelial growth factor A

The Role of the VEGF Signaling Pathway in Tumor Angiogenesis

The biology of VEGF and its receptors

Targeting angiogenesis in oncology, ophthalmology and beyond

Vascular endothelial growth factor signaling in development and disease

VEGF in biological control

The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions

Vascular endothelial growth factor-D: signaling mechanisms, biology, and clinical relevance

Ten years of anti-vascular endothelial growth factor therapy

Vascular endothelial growth factor in eye disease

VEGFR-2 Inhibitors and the Therapeutic Applications Thereof: a Patent Review (2012-2016)

Vascular Endothelial Growth Factor C and D Signaling Pathways as Potential Targets for the Treatment of Neovascular Age-Related Macular Degeneration: A Narrative Review

Recent advances and future directions on small molecule VEGFR inhibitors in oncological conditions

Anti-angiogenic drug discovery: lessons from the past and thoughts for the future

VEGF: From Discovery to Therapy: The Champalimaud Award Lecture

Vascular Endothelial Growth Factor: A Translational View in Oral Non-Communicable Diseases

Molecular Bases of VEGFR-2-Mediated Physiological Function and Pathological Role

VEGF-A/VEGFR2 signaling network in endothelial cells relevant to angiogenesis

Building on the success of anti-vascular endothelial growth factor therapy: a vision for the next decade

Research Progress of VEGFR Small Molecule Inhibitors in Ocular Neovascular Diseases